Additional investigations are necessary to assess the impacts of combination inhibition of UCP2 and mTOR/HIF‐1α by targeted drugs, which may provide a novel treatment strategy for NSCLC. The gene discussed is MTOR; the disease is non-small cell lung carcinoma.